BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ToleroMune cat allergy therapy: Phase II data

A double-blind, Canadian Phase II trial in 202 patients with confirmed cat allergies showed that 4 doses of ToleroMune met the primary endpoint of significantly reducing total rhinoconjunctivitis symptom score from baseline to week 12 vs. placebo (p=0.05). Specifically, Circassia said that...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >